Cargando…
Tumour and cellular distribution of activated forms of PR in breast cancers: a novel immunohistochemical analysis of a large clinical cohort
BACKGROUND: The progesterone receptor (PR) is expressed by ∼70% of early breast tumours and is implicated in the progression of breast cancer. In cancerous tissues PR may be activated in the absence of a ligand, or when ligand concentrations are very low, resulting in aberrantly activated PR (APR)....
Autores principales: | Bonneterre, Jacques, Bosq, Jacques, Jamme, Philippe, Valent, Alexander, Gilles, Erard M, Zukiwski, Alexander A, Fuqua, Suzanne A W, Lange, Carol A, O'Shaughnessy, Joyce |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070234/ https://www.ncbi.nlm.nih.gov/pubmed/27843626 http://dx.doi.org/10.1136/esmoopen-2016-000072 |
Ejemplares similares
-
Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers
por: Cottu, Paul H., et al.
Publicado: (2018) -
A decade of letrozole: FACE
por: O’Shaughnessy, Joyce
Publicado: (2007) -
A decade of letrozole: FACE
por: O’Shaughnessy, Joyce
Publicado: (2008) -
Treatment options for patients with HR+/HER2− advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy
por: O’Shaughnessy, Joyce
Publicado: (2020) -
The hedgehog pathway in triple‐negative breast cancer
por: Habib, Joyce G., et al.
Publicado: (2016)